XJPX
3628
Market cap57mUSD
Oct 09, Last price
715.00JPY
1D
0.14%
1Q
32.65%
Jan 2017
33.90%
IPO
178.57%
Name
Data Horizon Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Data Horizon Corporation offers specialized health data support solutions to insurance providers across Japan. The company develops and supplies medical information services, encompassing health-relevant data and notifications about generic drugs, alongside a comprehensive system designed to support health-related businesses. Founded in 1981, its headquarters are situated in Hiroshima, Japan. Data Horizon Corporation operates as a subsidiary of DeNA Co., Ltd.
Key people
Managing Executive Officer, Chief Director of Industry Business · since 2025
Kazuaki Hayashi
Managing Executive Officer, Chief Director of Operations & Development · since 2022
Tomohiro Matsuda
Managing Executive Officer, Chief Director of Business Planning · since 2025
Shinichiro Naito
Managing Executive Officer, Chief Director of Administration · since 2022
Kenji Nomura
Executive Officer, Deputy Chief Director of Sales
Koki Yoneda
Executive Officer, Deputy Chief Director of Sales · since 2022
Executive Officer, Deputy Chief Director of Data Health Business, Manager of CEO Office · since 2025
Kotaro Ito
Executive Officer, Chief Technology Officer · since 2025
Fumino Sakiyama
Executive Officer, Deputy Chief Director of Administration
Nagisa Kuraoka
Director · since 2022
Director · since 2022
President, Chief Executive Officer, Representative Director · since 2024
Yoshiyuki Towata
Managing Executive Officer, Chief Director of Data Health Business, Director · since 2025
Yoshio Utsumi
Chairman of the Board, Representative Director · since 2024
Jun Noma
Independent Director · since 2018
Tamotsu Okamoto
Independent Director · since 2022
Tetsuro Takeshima
Independent Director · since 2018
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||